हिंदी खबर
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg

ANI | Updated: Dec 21, 2020 11:52 IST


Mumbai (Maharashtra) [India], December 21 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg, the generic version of Pradaxa®1 Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIATM sales data for the 12 month period ending October 2020, the Pradaxa® Capsules, 75 mg, 110 mg, and 150 mg market2 achieved annual sales of approximately USD 550.9 million.
Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

Loading...
iocl
iocl